A study reveals attrition rates in patients with geographic atrophy on complement inhibitor therapies, highlighting the need for improved treatment adherence strategies.
Deepak Sambhara, MD
Advertisement
Deepak Sambhara, MD, is partner and medical director of research at the Eye Clinic of Wisconsin.
Articles by Deepak Sambhara, MD
At the Envision Summit 2025 in San Juan, Puerto Rico, Deepak Sambhara, MD, gave insight into the 96-week post hoc fluid outcomes analysis of patients who participated in the phase 3 clinical trial PULSAR.
Advertisement
Latest Updated Articles
Q&A: Deepak Sambhara, MD, discusses real-world follow-up for patients with GAPublished: June 6th 2025 | Updated:
Envision Summit 2025: PULSAR phase 3 trial 96-week post-hoc analysisPublished: February 16th 2025 | Updated:
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
News from Orlando: AAO 2025 highlights research across all areas of eyecare
3
AAO 2025: Philip J. Ferrone, MD, highlights safety and efficacy findings of gildeuretinol in Stargardt disease
4
AAO 2025: Glaucoma laser surgery with Joel S. Schuman, MD, FACS
5
.png "Optometry Times"){kind=logo}
